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Dorsal root ganglion (DRG) neurons process pain signaling through specialized
nociceptors located in their peripheral endings. It has long been established low
voltage-activated (LVA) CaV3.2 calcium channels control neuronal excitability during
sensory perception in these neurons. Silencing CaV3.2 activity with antisense RNA or
genetic ablation results in anti-nociceptive, anti-hyperalgesic and anti-allodynic effects.
CaV3.2 channels are regulated by many proteins (Weiss and Zamponi, 2017), including
KLHL1, a neuronal actin-binding protein that stabilizes channel activity by recycling it
back to the plasma membrane through the recycling endosome. We explored whether
manipulation of KLHL1 levels and thereby function as a CaV3.2 modifier can modulate
DRG excitability and mechanical pain transmission or sensitivity to pain. We first
assessed the mechanical sensitivity threshold and DRG properties in the KLHL1 KO
mouse model. KO DRG neurons exhibited smaller T-type current density compared to
WT without significant changes in voltage dependence, as expected in the absence of
its modulator. Western blot analysis confirmed CaV3.2 but not CaV3.1, CaV3.3, CaV2.1,
or CaV2.2 protein levels were significantly decreased; and reduced neuron excitability
and decreased pain sensitivity were also found in the KLHL1 KO model. Analogously,
transient down-regulation of KLHL1 levels in WT mice with viral delivery of anti-KLHL1
shRNA also resulted in decreased pain sensitivity. These two experimental approaches
confirm KLHL1 as a physiological modulator of excitability and pain sensitivity, providing
a novel target to control peripheral pain.
Keywords: voltage-gated calcium channel, T-type channel, mechanical sensitivity, pain control, KLHL1, CaV3.2,
DRG, shRNA
INTRODUCTION
Nociceptive pathways are generally activated in response to noxious stimuli as protection from
injury, yet chronic pain induces allodynia and hyperalgesia due to primary dysfunction, usually
caused by nerve injury. Long-term changes triggered by nerve injury include altered gene expression
in Dorsal root ganglion (DRG) and the spinal cord (Choi et al., 2007; Basbaum et al., 2009; Bourinet
et al., 2016). The role of low voltage-activated (LVA) calcium CaV3.2 channels in pain sensation is
well established; they contribute to nociception by lowering the threshold for action potential (AP)
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in DRG neurons (White et al., 1989; Cain and Snutch,
2010; Todorovic and Jevtovic-Todorovic, 2011). LVA channels
(also called T-type) are comprised of CaV3.1, CaV3.2, and
CaV3.3 channels; their biophysical properties such as the
relatively small depolarization required for their activation, and
window currents confer them the capability to act as burst firing
modulators (Cribbs et al., 1998; Perez-Reyes et al., 1998; Bourinet
et al., 2016).
T-type currents are up-regulated in various models of chronic
pain, such as chronic constriction injury, spinal nerve ligation,
STZ-diabetes, the carregin pain model, and drug-induced
diabetic neuropathy (Jagodic et al., 2007, 2008; Melrose et al.,
2007; Takahashi et al., 2010; Marger et al., 2011; Watanabe et al.,
2015; Li et al., 2017; Bellampalli et al., 2019). CaV3.2 can be
upregulated by increased expression of USP5, which interacts
with and de-ubiquitinates these channels thereby decreasing
their degradation (Garcia-Caballero et al., 2014; Stemkowski
et al., 2016). Moreover, treatment with T-type channel blockers
results in reduced mechanical hyperalgesia in the spinal nerve
ligation model (Dogrul et al., 2003; Chen et al., 2015). Similarly,
manipulation of the expression levels of CaV3.2, as in the KO
mouse model (Choi et al., 2007) or by selective knockdown
in DRG neurons using antisense (Bourinet et al., 2005) results
in attenuated pain responses, confirming the critical role of
CaV3.2 in pain transmission.
CaV3.2 are therefore viable pharmacological targets to control
pain (Dogrul et al., 2003; Flatters and Bennett, 2004; Okubo et al.,
2011; Chen et al., 2015). An alternative strategy to modulate
channel function is to target auxiliary or modulatory subunits
to indirectly affect channel activity or trafficking to the plasma
membrane (Weiss and Zamponi, 2019). This approach has been
highly successful in the modulation of high-voltage-activated
(HVA) channels by targeting of the α2δ subunit. This auxiliary
subunit enhances Ca2+ currents in part by modulating CaV
trafficking, altering their density and kinetics (Davies et al., 2007;
Hendrich et al., 2008) and is one of the molecular targets of the
antiepileptic and analgesic drug Gabapentin (GBP; Gee et al.,
1996; Suárez et al., 2005; Martins et al., 2015). Consequently,
treatment with GBP results in a significant decrease of N-type
CaV2.2 currents due to a reduction of functional channels at the
plasma membrane (Vega-Hernández and Felix, 2002; Hendrich
et al., 2008).
Here, we targeted a protein that affects CaV3.2 trafficking
to modulate its function and excitability in DRG neurons.
Our target is Kelch-like 1 (KLHL1), a structural protein
that binds to CaV3.2 and actin and alters CaV3.2 function.
KLHL1’s primary effect on CaV3.2 recycle it back to the
plasma membrane via direct association with the channel and
actin filaments, thus preventing its degradation; this process
is mediated through increased recycling endosome-mediated
channel insertion in the plasma membrane and results in
an increased number of functional channels and ultimately
increased CaV3.2-mediated T-type current density. KLHL1 also
remains bound to Cav3.2 and F-actin at the plasma membrane,
altering the channel kinetics of deactivation (Aromolaran
et al., 2009, 2010, 2012). Here, we show that the expression
levels of the structural protein KLHL1 can be altered to




DRG cultures were obtained as described (Gandini et al., 2014).
In brief, DRG were dissected from C57BL/6 mice (P6-P10) in
Advanced DMEM Medium (Gibco) supplemented with 20% of
Fetal Bovine Serum (Gibco), washed, and digested for 40 min
at 37◦C with a mixture of trypsin type XI (1.25 mg/ml, Sigma)
and collagenase IV (1.25 mg/ml, Sigma), followed by mechanical
dissociation. Cells were spun down at 1,000 g for 5 min at 10◦C
and re-suspended in Advanced DMEM medium supplemented
with 10% FBS. Cells were plated onto L-lysine-covered coverslips
(12 mm, Carolina Biological Supply, Burlington, NC, USA) and
kept in a 5% CO2 humidified atmosphere at 37◦C. The Patch-
clamp recordings were made 24 h after dissociation (1 day
in vitro, 1 DIV).
Biochemistry
Western blots. Crude protein was extracted from at least three
WT or KLHL1 KO DRG ganglia pooled together and separated
by SDS-PAGE electrophoresis (8%, at 100 V for 90 min) for
transfer to a PVDF membrane (BioRad). Membranes were
washed in Tris-buffered saline (TBS) supplemented with 0.05%
Tween 20 (TBST) and blocked for 1 h in TBST-5% milk at room
temperature (Florio et al., 1992). Membranes were incubated at
4◦C overnight with primary antibodies against CaV3.1 (1:1,000,
Millipore, CA, USA), CaV3.2 (1:2,000, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), CaV3.3 (1:1,000, Alomone), CaV2.1
(1:1,000, Alomone) or CaV2.2 (1:1,000, Alomone). GAPDH
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; 1:1,000)
was used as an internal reference to normalize for protein
loading. Horseradish peroxidase (HRP)-conjugated secondary
antibodies were used for detection (1:2,000; Pierce) with
Supersignal Femto (Pierce, IL, USA) using a ChemiDoc MP
System (BioRad).
Immunoprecipitation. Crude membrane preparations were
obtained using standard protocols (Aromolaran et al., 2010); a
fraction of the sample was reserved prior to immunoprecipitation
(input, 30× less concentrated than the IP samples) and the
remaining volume was divided up for all experiments. Samples
were processed by addition of primary antibodies (CaV3.2,
1:40 and KLHL1, 1:40, Santa Cruz Biotechnology, or IgG,
1:40, Alpha Diagnostic Intl. Inc., San Antonio, TX, USA) and
incubated for 1–3 h at 4◦C followed by overnight incubation
with protein A/G agarose beads (Biovision, Mountain View, CA,
USA) on a shaking plate at 4◦C. Samples were washed and
processed for western blot analysis as described.
Electrophysiology
Whole-cell patch-clamp recordings were obtained at 1DIV
using an Axopatch 200B amplifier (Axon Instruments, Union
City, CA, USA) at room temperature. Data were acquired
at 1 kHz and digitized at 20 kHz. Calcium currents were
recorded using an external solution containing (in mM)
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5 CaCl2, 140 TEA-Cl, 10 HEPES and 10 glucose (pH 7.4,
300 mosmol/kgH2O). The intracellular solution contained (in
mM): 108 CsMeSO3, 4 MgCl2, 10 Cs-EGTA, 9 HEPES, 5 ATP-
Mg, 1 GTP-Li and 15 phosphocreatine-Tris. Pipette resistances
were 3.0–4.0 M. Series resistance (Rs) was compensated
online (>80%), only cells with Rs <15 M were used.
Data were acquired and analyzed using pClamp10 software
(Molecular Devices).
Total currents were elicited using depolarizing steps (test
potentials, VT) from −60 to +60 mV (∆V = 10 mV) from a
holding potential (VH) of−90 mV. HVA currents were obtained
from VH = −50 mV to VT = −60 to +60 mV (∆V = 10 mV).
HVA currents traces were subtracted from the total current
traces at each VH to obtain the LVA current component.
APs were measured using an external solution containing
(in mM): 135 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES,
10 glucose; the intracellular solution composition was (in mM)
110 K-gluconate, 20 KCl, 2 MgCl2, 1 EGTA, 10 HEPES, 2 ATP-
Mg, 0.25 GTP-Li and 10 phosphocreatine-Tris. The APs were
triggered by four consecutive 1.5-s-long current depolarizing
ramps at 20, 40, 60, or 80 pA/s. Rheobase was determined as the
minimum current necessary to elicit an AP from a membrane
potential of−75 mV.
Viral Production
Adeno-associated viral constructs containing small
hairpin RNAs (shRNA) targeting KLHL1 were designed;
shKLHL1-AAV contained two sequences from the
mouse gene (NM_053105.2) spanning nucleotides (nt)
1,812–1,830 and 2,121–2,139 (GGCCAGTGATGATGTAAAT
and GGGAATGGATAATAACAAA, respectively); these
segments were synthesized and cloned into an AAV shuttle
vector pZacf-U6-Luc-Zsgreen (U Penn Gene Therapy Core) as
described before (Zolotukhin et al., 1999; Sarkey et al., 2011).
These shuttle plasmids, along with pHelper and pAAV2/8 were
transfected into AAV-293 cells using the Virapack transfection
kit (Stratagene) and purified by an iodixanol step gradient as
described before (Pradhan et al., 2010). Titer was assessed by
serial dilutions of virus and infection of HT1080 cells. AAV
particle titer was quantified by SDS-PAGE (Zolotukhin et al.,
1999; Kohlbrenner et al., 2012). EGFP-AAV was generated in
house by the same method.
AAV Injections
All animal protocols used in this study were reviewed and
approved by an independent Institutional Animal Care and Use
Committee (IACUC). Hind paws of 13- weeks old WT male
mice were injected with a control virus (EGFP-AAV, shCtrl,)
or shKLHL1-AAV under blind conditions. The summary of
the experimental conditions used is depicted in Figure 6A.
The initial trial (n = 7) received 4.2 × 1010 shKLHL1-AAV
or 5.5 × 1010 EGP-AAV vector genomes. The second trial
(n = 11) received a high titer, 9.0 × 1010 shKLHL1-AAV or
EGFP-AAV vector genomes over 2 days. Viruses were diluted
such that each individual injection volume was 5 µl total.
Mice were given pain medication (Buprenorphine, 0.05 mg/kg,
s.c.) for the first 2 days following the last injection and were
allowed to recover in observation for 4–5 days while checked
for any limp or lameness; all mice were confirmed healthy
after injections.
Behavioral tests were performed twice a week (and
averaged) for a total of 3 weeks after injections. Baseline
withdrawal threshold responses were determined for 1 week
before injections.
% Paw-withdrawal threshold was reported as the % of mice
in the total population displaying withdrawal thresholds at all
forces tested.
Von Frey Filament Tests
Hind paw withdrawal experiments were carried out in male mice
∼16 weeks old; animals had access to food and water ad libitum,
all experiments followed IACUC-approved standard procedures.
Only males were used in the first study because our preliminary
data show male KLHL1 KO mice display a clear phenotype in
contrast with females, where differences are more difficult to
establish if present. Mice were placed on a wire mesh-bottom
testing apparatus and allowed to acclimate for 15 min before
assessing mechanical allodynia. Measurements were recorded
by applying von Frey filaments (North Coast, Morgan Hill,
CA, USA) ranging from 1.4 to 10 g to the plantar surface of
the mouse hind paw; each filament was assessed for a total of
five consecutive times. Hind paw withdrawal response times of
less than 2 s were considered positive. The withdrawal threshold
was calculated as the filament force at which each mouse had
a positive response more than three times out of five (Chaplan
et al., 1994; Bonin et al., 2014).
DRG Slices
Mice were anesthetized with isoflurane before euthanasia;
DRG were excised and fixed with 4% paraformaldehyde
for 4 h, cryoprotected overnight (30% sucrose in PBS),
embedded in OCT (Tissue Tek, Fisher Scientific, Hampton,
NH, USA), and frozen with dry ice. 30 µm-thick sections
were cut using a cryostat and mounted onto Superfrost Plus
slides (Fisher Scientific, Hampton, NH, USA). Slides were
washed three times with PBS-glycine, dried and protected
with coverslips. Fluorescence images were captured using
IX80 Olympus inverted epifluorescence microscope using a 10×
objective and analyzed using deconvolution.
Statistical Analysis
Statistical analysis was performed with SigmaPlot 11 Software.
Statistical significance was determined as P < 0.05, using
student’s t-test or Kolmogorov–Smirnov non-parametric
analysis (Kolmogorov–Smirnov test). Results are presented as
mean± SEM.
RESULTS
KLHL1 Is Expressed and Interacts With
CaV3.2 in DRG Neurons
Co-immunoprecipitation of CaV3.2 and KLHL1 is detected in
overexpression experiments in HEK-293 cells and in whole
brain samples, demonstrating direct interaction between these
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FIGURE 1 | CaV3.2 and KLHL1 interact in mice dorsal root ganglion (DRG)
ganglia. Co-immunoprecipitation of CaV3.2 and KLHL1 using antibodies
against CaV3.2 (top) and KLHL1 (bottom).
two proteins (Aromolaran et al., 2009, 2010, 2012). Figure 1
shows an example of pull-down experiments from DRG protein
extracts using CaV3.2 (top) or KLHL1 antibodies (bottom, IgG
was used as negative control). These data confirm the presence
of KLHL1 in DRG neurons and its interaction with CaV3.2
T-type channels.
KLHL1 KO DRG Neurons Exhibit Low
CaV3.2 Channel Expression and Reduced
Excitability
We next assessed the effect of KLHL1 deletion on CaV
expression in DRG neurons. HVA channel expression was
statistically similar in both KLHL1 KO and WT mice, as seen
in Figure 2, which shows the KO/WT protein ratio for CaV2.1
(1.3 ± 0.4, n = 4) and CaV2.2 (1.0 ± 0.1, n = 3). In contrast,
CaV3.2 expression was statistically lower among LVA channels
(0.3 ± 0.09, n = 4) in the KLHL1 KO tissue (p = 0.04) whereas
CaV3.1 and CaV3.3 expression remained constant (1.0 ± 0.2,
n = 3; and 0.9 ± 0.06, n = 4 respectively). Thus, the absence of
KLHL1 results in decreased CaV3.2 protein expression, which
remains uncompensated for in the adult KLHL1 KO mice DRG.
To assess the physiological impact of lower CaV3.2 expression
in the absence of KLHL1 we analyzed Ca2+ current densities in
DRG neurons. We found two neuronal populations according to
the Ca2+ currents they expressed (Figure 3A): 56% of all WT
neurons elicited only HVA currents (capacitance = 23.0± 3.1 pF,
n = 14; gray symbols); the remaining cells (44%) expressed
both HVA and LVA currents. The latter group had an average
capacitance of 18 pF ± 2.4 pF (black symbols, n = 11); this
value was not statistically different from HVA-only neurons
(p = 0.1).
Overall the HVA-only population was identical between
WT and KLHL1 KO neurons (56% and 53% of the total
population, respectively), with current densities of 45.1± 5.9 and
50.1 ± 7.9 pA/pF (n = 10 and 13 (WT, KO); p = 0.1). Figure 3B
depicts an example of a recording from a neuron displaying HVA
currents-only. Figure 3C shows the I-V curves for WT (black
FIGURE 2 | Lower CaV3.2 expression in KLHL1 KO DRG. (A) Western Blot
example of CaV3.2 expression. GAPDH was used as loading control.
(B) Densitometric quantification of voltage-gated calcium channel protein
levels by Western Blot analysis of high-voltage-activated (HVA; CaV2.1 and
CaV2.2) and low voltage-activated (LVA; T-type; CaV3.1, CaV3.2, and CaV3.3)
α subunits. Protein levels are expressed as KO/WT ratio ± SEM (n = 3;
CaV2.1 and CaV3.2, n = 4; ∗p < 0.05, student’s t-test).
circles) and KO HVA-only neurons (white circles; n = 10, 13;
p = 0.2).
Neurons expressing LVA+HVA currents represented 44% of
the total population in WT vs. 47% in KO neurons (p = 0.1).
Figure 3D depicts an example of HVA+LVA currents; the
rapidly inactivating LVA current component is noticeable at
lower voltages. Figure 3E shows an example of current traces
recorded at VT = −30 mV from VH = −90 and from
−50 mV, respectively, which when subtracted yield the LVA
current component (red trace). Figure 3F shows the LVA-only
current I–V curves from WT and KO DRGs. The peak LVA
current was −37.0 ± 3.6 pA/pF (n = 11) in WT compared to
−23.0± 4.6 pA/pF (n = 10) in the KO (at−30mV; p = 0.004).We
studied small neurons with capacitances ranging from 18 to 28 pF
to ensure only nociceptor neurons were analyzed (Andrade et al.,
2010), given that D-Hair cells also display a high density of T-type
currents (Dubreuil et al., 2004; Coste et al., 2007; Bernal Sierra
et al., 2017), but their capacitance ranges from ∼39 to 65 pA
(Coste et al., 2007).
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FIGURE 3 | Lower T-type current density in KLHL1 KO DRG neurons. (A) Distribution of current profiles found in WT DRG neurons and their I–V relationships: 56%
neurons expressed only HVA currents (black symbols) and 44% expressed a mixture of LVA + HVA currents (gray symbols). (B) Representative Ca2+ currents
recorded from a small DRG neuron (23 pF) expressing HVA currents only; the voltage protocol is shown above the traces (mV). (C) I–V curves for HVA-only currents
recorded from WT (black) and KO neurons (white), VH = −90 mV. (D) Representative traces of a neuron displaying both LVA and HVA Ca2+ currents.
(E) Representative LVA current trace (red) obtained by current subtraction. (F) I-V curves of the subtracted LVA component for WT (black) and KO (white; n = 10, 11;
∗p < 0.004).
The impact of decreased CaV3.2 channel expression on
DRG neuron excitability was assessed using current clamp
experiments. Figure 4A shows representative traces of the APs
elicited by a depolarizing current ramp delivered at 60 pA/s.
The KLHL1 KO neuron rheobase was significantly larger
(39.0 ± 4.1 pA) than WT (22.1 ± 2.9 pA; n = 9, 11, p = 0.03;
Figure 4B), in line with a reduction in LVA calcium channel
expression. This increase was accompanied by a concomitant
reduction in action potential number (AP; 9.2 ± 1.1, n = 9)
compared to WT (13.1 ± 1.4, n = 11, p = 0.03; Figure 4C).
This rheobase difference was abolished by application of a low
dose (100 nM) of NCC 55–0396 (NCC) to partially block T-type
channels in WT neurons (27.2± 3.7 pA, n = 8, p = 0.003).
KLHL1 Mice Display Increased Mechanical
Sensitivity Threshold
Our data shows that CaV3.2 expression is down-regulated in
the absence of KLHL1; KO DRG neurons display significantly
lower neuronal excitability, which may, in turn, alter pain
sensation. We assessed the responses to mechanical stimulation
by measuring paw withdrawal thresholds in WT and KLHL1 KO
mice using von Frey filaments. KLHL1 KO mice displayed
significantly higher withdrawal threshold (6.1 ± 0.2 g, n = 20)
compared toWTmice (4.7± 0.3 g, n = 20; p = 0.009; Figure 5A).
Non-parametric analysis of paw withdrawal threshold responses
within the mice population demonstrates statistical differences
at 4 and 6 g of force (p < 0.05; Figure 5B). Thus,
decreased CaV3.2 expression in KLHL1 KO DRG neurons
results in decreased excitability and altered pain sensitivity,
confirming KLHL1 is a physiological modulator of CaV3.2 in
sensory neurons.
Modulation of KLHL1 Expression Levels
Alters Mechanical Sensitivity in WT Mice
Induction of excitability changes by the manipulation of
KLHL1 levels could represent a novel method in the regulation
of Cav3.2 expression. Therefore, we tested whether knockdown
of KLHL1 expression alters mechanical sensitivity in WT mice
by injecting adeno-associated viral particles (AAV) containing
shRNA designed against KLHL1 into the mice hind paws (US
Patent 10,047,377).
Preliminary data from neuronal cultures indicated that titers
∼5.0 × 1010 shRNA-containing viral particles appeared to be
less efficient in vitro. Therefore, we carried out two blind trials
assessing the effect of two titer viral loads (4.2 × 1010 vs.
9.0 × 1010 viral particles; Figure 6A). All trials were performed
following the timeline showed in Figure 6B and described in
‘‘Materials and Methods’’ section.
Figure 6C shows representative images of DRG slices
obtained fromWT mice injected with EGFP-AAV or shKLHL1-
AAV, confirming successful delivery and uptake of the AAV.
CaV3.2 and KLHL1 levels from protein samples pooled from
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 January 2020 | Volume 12 | Article 315
Martínez-Hernández et al. KLHL1 Modulates Mechanical Nociception
FIGURE 4 | The absence of KLHL1 alters DRG neuron excitability.
(A) Examples of action potential (AP) trains generated by a depolarizing ramp
rate of 60 pA/s in WT, KLHL1-KO and WT + 100 nM of NCC 55–0396 DRG
neurons. (B) Rheobase values. (C) Average number of APs (WT, n = 10, KO,
n = 11, WT + NCC, n = 7; ∗p = 0.003).
FIGURE 5 | KLHL1 KO mice are less sensitive to mechanical stimulation.
(A) Paw withdrawal threshold in response to mechanical stimulation,
expressed as g of force (n = 20, WT and KO; ∗p < 0.05). (B) Data expressed
as cumulative % of the population of mice responding at a given force; PWT,
paw withdrawal threshold (∗p < 0.05, non-parametrical
Kolmogorov–Smirnov test).
three L4 DRGs ipsilateral to the shKLHL1-AAV-injected paw
were analyzed by western blot (sh). L4 DRG ipsilateral to the
EGFP-AAV injection were also collected as a negative control
(Ctrl; Liu et al., 2019).
Baseline behavioral tests were performed a week prior
to injection in all mice (untreated). Blinded experimental
measurements started 4–5 days after AAV injection and were
performed 2–3 times weekly for 3 weeks thereafter (Figure 7).
As seen in all figures, baseline withdrawal threshold values were
indistinguishable in mice injected with either EGFP-AAV or
shKLHL1-AAV at both titers, trial 1: EGFP-AAV, 5.2 g vs. 5.0 g
for shKLHL1-AAV2; n = 7, p = 0.2; trial 2: EGFP-AAV, 5.2 g vs.
5.5 g in shKLHL1-AAV; n = 11, p = 0.2).
FIGURE 6 | KLHL1 knockdown with shKLHL1-AAV leads to
CaV3.2 down-regulation. (A) Experimental conditions used. (B) Timeline of
behavioral experiments. (C) Example of DRG slices from mouse injected with
control EGFP-AAV and shKLHL1-EGFP AAV; size bar, 100 µM.
AAV injections caused some pain and inflammation, as
expected (Ishihara et al., 2012), resulting in lower threshold
values after injection compared with untreated values, as seen
after injection in trial 1 at weeks 1–3 compared to untreated.
Overall, the doses of shKLHL1 delivered in trial 1 exerted
no effect on mechanical sensitivity, as seen in Figure 7A; the
individual weekly averages were: week 1: EGFP-AAV, 4.4± 0.4 g
vs. 4.1 ± 0.3 g for shKLHL1-AAV-2 (n = 7, p = 0.2); week 2:
EGFP-AAV, 4.0 ± 0.2 g vs. 4.2 ± 0.2 g for shKLHL1-AAV-
2 (n = 7, p = 0.3); and week 3: EGFP-AAV = 4.2 ± 0.2 g vs.
4.7± 0.1 g in shKLHL1-AAV-2 (n = 7, p = 0.056).
The dose delivered in trial 2 (∼9.0 × 1010 viral particles,
Figure 7B) induced significant differences in mechanical
threshold values in shKLHL1-injected mice after 1 week. Unlike
trial 1 and trial 2 control conditions, mechanical thresholds
in shKLHL1-injected mice did not decrease compared to
untreated conditions and they were significantly higher than
their corresponding controls at all times tested. Week 1: EGFP-
AAV, 3.6 ± 0.3 g vs. 4.6 ± 0.5 g for shKLHL1-AAV-1 (n = 11,
p = 0.006); week 2: EGFP-AAV, 3.8 ± 0.5 g vs. 5.8 ± 0.3 g for
shKLHL1-AAV-1 (n = 11, p = 0.006); and week 3: EGFP-AAV,
3.5± 0.4 g vs. 5.6± 0.5 g for shKLHL1-AAV-1 (n= 11, p= 0.001).
Further analysis is shown in Figure 8 where trial 2 data
is shown as the percentage of the mice population displaying
paw withdrawal threshold (PWT %) at a given Von Frey
filament force value. There are no significant differences in
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FIGURE 7 | KLHL1 knockdown decreases mechanical sensitivity. (A)
Average withdrawal threshold response to mechanical stimulation after
injection with EGFP-AAV (black) or shKLHL1-AAV (red) at low titer of
shKLHL1 or EGFP-AAV. (B) The average response from delivery of high titer
shKLHL1-AAV or EGFP-AAV virus, ∗p ≤ 0.006.
FIGURE 8 | Cumulative response in the high dose trial. Data from trial
2 expressed as the cumulative response in the mice population after a given
stimulus. (A) Untreated mice. (B–D) Responses after 1, 2 and 3 weeks of
EGFP-AAV (black symbols) and shKLHL1-AAV (red symbols) injection,
∗p < 0.05.
baseline values (A) or after the first week after injection (B)
between the experimental and control-treated mice populations
(Kolmogorov–Smirnov test). However, 69% of EGFP-AAV
injected mice responded to the 4 g von Frey filament stimulus
2 weeks after injection (C) in comparison with only 34% in the
shKLHL1-AAV injected population (p < 0.05). This difference
was more pronounced after 3 weeks of injection (D), with
changes between the two populations at 4 g (35% shKLHL1-AAV
vs. 64% EGFP-AAV) and 2 g (0% shKLHL1-AAV vs.
24% EGFP-AAV). Note that all mice were more sensitive
after injections as a result of the AAV injections (compare
to untreated).
DISCUSSION
T-type CaV3.2 channel up-regulation is associated with diabetic
neuropathy (Jagodic et al., 2007), neuropathic pain (Choi et al.,
2016) and irritable bowel syndrome (Marger et al., 2011).
Similarly, increased CaV3.2 function is found in chemotherapy-
induced toxic neuropathies, and their inhibition with T-type
calcium channels blockers decreases pain sensitivity (Flatters
and Bennett, 2004; Okubo et al., 2011; Li et al., 2017). Also,
paracetamol fails to induce analgesic effects in CaV3.2 knockout
mice, suggesting these channels are necessary for analgesic
actions (Kerckhove et al., 2014).
KLHL1 protein is a constitutive modulator of
CaV3.2 channels, and here we show that in its absence,
KLHL1 KO mice elicit increased mechanical sensitivity
threshold (decreased sensitivity to pain). Thus, KLHL1 could
have significant potential as a molecular target to modulate
neuropathic pain, akin to the effect of the auxiliary subunit
α2δ’s role on HVA channels (Field et al., 2006; Nguyen
et al., 2009). KLHL1 functions in an analogous manner
as the α2δ subunit, which is targeted by GBP and similar
drugs resulting in a significant decrease of CaV2.2 currents
in part by a reduction of functional channels at the plasma
membrane (Vega-Hernández and Felix, 2002; Field et al., 2006;
Hendrich et al., 2008; Aromolaran et al., 2009, 2010, 2012;
Martínez-Hernández et al., 2011).
KLHL1 KO neurons displayed decreased T-type calcium
current density due to the down-regulation of CaV3.2, they also
displayed decreased DRG neuron excitability, in line with the
absence of KLHL1. Partial blockade of T-type channels with
100 nM NCC 55–0396 in WT neurons reduced their excitability
to a comparable level to that of the KO DRGs, suggesting T-type
channel down-regulation is solely responsible for the decrease
in excitability.
Similar to other studies (Shin et al., 2003; Wang et al., 2015),
we found CaV3.1 expression is detectable in DRG neurons
from mice (in contrast to studies performed in rats, which
report CaV3.1 is absent in DRG neurons from that species
(Talley et al., 1999; Wen et al., 2006), however, it is well
established that CaV3.1 does not have a functional role in
DRGs, and accordingly, RNAseq data, Allen Atlas data and
our own ICC data (not shown) demonstrate CaV3.1 expression
in DRG is much lower in mice (if present) compared to
CaV3.2. The fact that CaV3.1 is not physiologically relevant
in DRG neurons possibly explains our observation that this
channel type was not upregulated in KLHL1 KO DRG
neurons, in contrast with our observations in hippocampal
neurons from KLHL1 KO (Perissinotti et al., 2014). Similarly,
KLHL1 also interacts with CaV2.1, and their levels were
also unaffected in this system (in contrast to KLHL1 KO
hippocampal neurons). The cause of this differential regulation
is not known yet but may again be because CaV2.1 is
not physiologically relevant in DRG neurons, thus suggesting
tissue-specific modulatory mechanisms are tuned to control
the expression of functionally relevant channels and their
isoforms differently in central nervous system (CNS) vs. DRG-
neurons (Zamponi and Snutch, 2013).
Administration of T-type calcium channels blockers such
as mibefradil or ethosuximide via intraperitoneal or paw
injection, or chronic intrathecal infusion show reversal of
neuropathic pain in rats (Dogrul et al., 2003; Chen et al.,
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2015); similarly, knockdown of CaV3.2 resulted in decreased
analgesic effect (Bourinet et al., 2005, 2016). Here, we were
able to alter mechanical sensitivity in WT mice by knocking
down KLHL1 levels in DRG neurons using anti-KLHL1 shRNA
AAV injected into the hind paws of WT mice. We were able
to sample the decreased expression of KLHL1 and CaV3.2
T-type channels by Western Blot analysis in a sample of three
pooled L4 DRGs injected with shKLHL1 AAV compared to
an EGFP AAV- injected DRGs sample. von Frey filament
tests confirmed that mice whose hind paws were injected
with shKLHL1 were less sensitive to pain than those injected
with control EGFP-AAV (5.6 ± 0.5 g threshold compared to
3.5 ± 0.4 g, respectively at week 3 of treatment). These values
are in line with the majority of data in the literature (Watanabe
et al., 2015; Garcia-Caballero et al., 2016; M’Dahoma et al.,
2016; Stemkowski et al., 2016; Ogawa et al., 2018); however,
two groups have reported withdrawal threshold values around
1 g (Costigan et al., 2009; Chiu et al., 2013; Vicuna et al.,
2015; Choi et al., 2016). It is no clear the reason for these
differences, given that most studies were done using C57B/6mice
(6–14 weeks old).
In vitro data from neuronal cultures indicated that viral
titers of less than 5.0 × 1010 particles would be less
efficient, here we found we found that in vivo delivery of
5.1 × 1010 shKLHL1-AAV vector genomes was the minimal
titer that exerted an effect, although it was only attained after
3 weeks post-treatment. In contrast, delivery of 9.0 × 1010
vector genomes of virus-containing shKLHL1 sequences was
efficacious at increasing the mice’s withdrawal threshold,
demonstrating reduced sensitivity to pain. Alternative delivery
routes such as subcutaneous or intramuscular injections are also
known as viable options, and can be assessed in the future
(Towne et al., 2009).
In summary, our study shows that KLHL1 is a physiological
modulator CaV3.2 expression and function in DRG neurons
and that KLHL1 may be a viable molecular target to reduce
pain transmission by lowering CaV3.2 expression. Modulation
of neuronal excitability by alteration of KLHL1 levels and/or
function may represent a novel method of treatment for
neuropathic disorders and may help facilitate the development
of novel therapeutic alternatives.
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